Category: Research

What’s next for healthcare as Dems take the Senate?

published date
January 6th, 2021 by

It’s a momentous week in Georgia, Washington and these United States. In this special episode of the HealthBiz podcast, Bloomberg Intelligence Analyst, Brian Rye and I discuss the health policy implications of the likely 50+1 Democratic Senate majority. Listen in as we discuss drug pricing, Medicare Advantage, and the public option.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle Podcasts and  many more services. Please consider rating the podcast on Apple Podcasts. Doing so helps the podcast reach more listeners.

Check out the rough (AI generated) transcript.


By healthcare business consultant David E. Williams, president of Health Business Group.

ICER founder Dr. Steve Pearson explains COVID-19 remdesivir pricing model

published date
November 12th, 2020 by

Steve scaled e1603726353244
Dr. Steve Pearson

Drug pricing is the hottest topic in healthcare, and ICER founder Dr. Steve Pearson is the coolest person to discuss it with.

In this episode of the HealthBiz podcast, Steve describes how the Institute for Clinical and Economic Review (ICER) compiles and analyzes clinical evidence to estimate the fair value of treatments for cancer and other serious illnesses. ICER has been especially active during the pandemic, developing a pricing model for remdesivir and other COVID-19 therapies that’s being used in the United States and by health technology assessment agencies around the world.

For fun, he has been reading Paradise Lost by John Milton.

This is the second episode I’ve recorded on COVID-19 drug pricing. Check out the first one: Remdesivir powers activate! with Dr. Surya Singh.

The HealthBiz podcast is now on SpotifyApple PodcastsGoogle Podcasts and  many more services, making it easy to subscribe.

Below is a rough (AI-generated) transcript of the episode.



—–

By healthcare business consultant David E. Williams, president of Health Business Group

 

Data will eat public health: Podcast with Shahir Kassam-Adams

published date
September 24th, 2020 by

The HealthBiz podcast is now on Spotify and will soon be on many more services making it easy to subscribe.

shahir photo
Shahir Kassam-Adams

Shahir Kassam-Adams is one of the most knowledgeable and outspoken people in healthcare. In this episode, Shahir shares his initially unsettling but ultimately reassuring view that “data will eat public health.” He opines on interoperability and explains how his company, Datavant has promoted data sharing on COVID-19, leading to a plethora of interesting and potentially useful projects, including one that models the tradeoffs for specific American cities to reopen.

Check out the links:

—–

By healthcare business consultant David E. Williams, president of Health Business Group

Russia rushes its COVID-19 vaccine. Why all is not what it seems

published date
August 10th, 2020 by
honor guard 67636 1280
Any volunteers?

Russia –yes the Russia that exerts special influence on our president– has done a poor job of keeping the COVID-19 virus in check. But now they claim to have a safe and effective vaccine that’s ready to go.

I’m quoted in the International Business Times (Questions Surround Russia’s Ability to Deliver a Safe, Effective Coronavirus Vaccine)

Some suggest that the vaccine may not be safe – or effective.

“It’s obvious that the Russians are rushing the vaccine to market without adequate testing,” David Eugene Williams, president at Health Business Group, told International Business Times in an email. “It’s possible that the vaccine will work, but there hasn’t been enough time to verify that it’s both safe and effective. The Russians haven’t released any data that would support their claims.”

“I don’t think people will travel to Russia to receive the vaccine because, 1) they won’t trust that it will work, 2) they could get COVID-19 on their travels to Russia, and 3) the Russians may allocate it to their own citizens,” he said.

It would be great if the Russian vaccine works. But we’ll have to wait and see –which is something the developers haven’t done.


By healthcare business consultant David E. Williams, president of Health Business Group.

What do patients think of virtual care? Interview with Kyruus’s Dr. Erin Jospe

published date
July 31st, 2020 by
Erin Jospe headshot
Dr. Erin Jospe, Kyruus CMO

Patients have been receiving a megadose of virtual care since March. How’s it going and what will it mean long-term? Provider search and scheduling company, Kyruus asked 1000 patients for their opinions and published the findings.

How Patients Learned About Virtual Care Options
How Patients Learned About Virtual Care Options

Kyruus Chief Medical Officer, Dr. Erin Jospe and I had a chance to catch up on the report and speculate about its implications in this podcast.

Here’s what we discussed:

  • (0:15) Key findings and surprises
  • (1:54) Baby Boomers’ affinity for virtual care
  • (3:40) Paradox that Baby Boomers are big utilizers of virtual care but not so likely to switch doctors to get it
  • (6:21) Downsides and limitations of virtual care
  • (10:55) Impact of virtual care on disparities
  • (13:47) Potential to launch a virtual-first practice
  • (17:31) Why Kyruus cares about these results

—-

Interview conducted by healthcare business consultant David E. Williams, president of Health Business Group. Podcast production by Marina Zapesochny, social media intern.